Stephanie K Rigot

Dr. Stephanie K Rigot

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2021 in Archives of Physical Medicine and Rehabilitation
Verified
Journal Article
Closed access
SRStephanie K Rigot
Stephanie K Rigot
LWLynn A. Worobey
Lynn A. Worobey
MBMichael L. Boninger
Michael L. Boninger
SRSusan Robinson-Whelen
Susan Robinson-Whelen
MRMary Jo Roach
Mary Jo Roach
GMGina McKernan
Gina McKernan

1 April 2022 in Archives of Physical Medicine and Rehabilitation
Verified
Journal Article
Closed access
SRStephanie K Rigot
Stephanie K Rigot
MBMichael L. Boninger
Michael L. Boninger
DDDan Ding
Dan Ding
GMGina McKernan
Gina McKernan
EFEdelle C. Field-Fote
Edelle C. Field-Fote
LWLynn A. Worobey
Lynn A. Worobey

18 August 2024 in Sleep Medicine
Verified
Journal Article
Open access
HSHaramandeep Singh
Haramandeep Singh
FBFiona C. Baker
Fiona C. Baker
JOJoseph Ojile
Joseph Ojile
BABahman Adlou
Bahman Adlou
VKViktoriia Kolotovska
Viktoriia Kolotovska
JCJonathan D. Charlesworth
Jonathan D. Charlesworth
There is a significant unmet need for safe and effective nonpharmacological therapies for restless legs syndrome (RLS). The objective was to evaluate the efficacy and safety of tonic motor activation (TOMAC) in patients with RLS. A multicenter, randomized, participant-blinded, sham-controlled trial enrolled 45 adults with primary moderate-to-severe RLS who were either medication-naïve (n = 20) or medication-refractory (n = 25). Participants were 1:1 randomized to TOMAC (n = 22) or sham (n = 23) for two weeks and instructed to self-administer 30-min TOMAC sessions when they experienced RLS symptoms. The primary outcome was mean change in International RLS Study Group Rating Scale (IRLS) total score. A subsequent meta-analysis included the present trial and a previous randomized clinical trial that enrolled medication-naïve RLS patients. IRLS reduction was significantly greater for TOMAC than sham (TOMAC -6.59 vs. sham -2.17; mean difference (MD) = -4.42; 95 % confidence interval [CI] -1.57 to -7.26; p = 0.0040). Subgroup analysis showed similar IRLS mean difference for medication-refractory (MD = -4.50; p = 0.02) and medication-naïve (MD = -4.40; p = 0.08) cohorts, which was significantly different from sham only for the medication-refractory cohort. Meta-analysis of combined data from 33 medication-naïve RLS patients showed a significant reduction in mean IRLS score after two weeks for TOMAC compared to sham (MD = -4.30; 95 % CI -1.36 to -7.24; p = 0.004). The present trial confirmed previous reports documenting efficacy and safety of TOMAC in refractory RLS and indicated similar effect sizes in refractory versus naïve subgroups. The meta-analysis demonstrated that TOMAC significantly improves RLS symptoms in naïve participants.

30 March 2023 in Spinal Cord Series and Cases
Verified
Journal Article
Open access
PDF file
LALibak Abou
Libak Abou
LWLynn A. Worobey
Lynn A. Worobey
SRStephanie K Rigot
Stephanie K Rigot
ESElizabeth Stanley
Elizabeth Stanley
LRLaura Rice
Laura Rice
Study design Cross-sectional study. Objective To evaluate the reliability of home-based remote and self-assessment of transfer quality using the Transfer Assessment Instrument (TAI) among wheelchair users with spinal cord injury (SCI). Setting Participant’s home environment. Methods Eighteen wheelchair users with SCI transferred from their wheelchair to a surface of their choice (bed, sofa, or bench) in their homes. During a live video conference, the transfer was recorded and evaluated live using the TAI (rater 1). Participants completed a self-assessment of their transfer using the TAI- questionnaire (TAI-Q). Two additional raters (raters 2 & 3) completed asynchronous assessments by watching recorded videos. Interrater reliability was assessed using Intraclass Coefficient Correlations (ICC) to compare rater 1 with the average of raters 2 & 3 and TAI-Q. Intrarater reliability was assessed by rater 1 completing another TAI by watching the recorded videos after a 4-week delay. Assessments were compared using paired sample t-tests and level of agreement between TAI scores was evaluated using Bland–Altman plots. Results Moderate to good interrater and good intrarater reliability were found for the total TAI score with ICCs: 0.57–0.90 and 0.90, respectively. Moderate to good intrarater and interrater reliability were found for all TAI subscores (ICC: 0.60–0.94) except for interrater reliability of flight/landing which was poor (ICC: 0.20). Bland–Altman plots indicate no systematic bias related to the measurement of error. Conclusions The TAI is a reliable outcome measure for assessing the wheelchair and body setup phases of home-based transfers remotely and through self-assessment among individuals with SCI.

3 November 2022 in Journal of NeuroEngineering and Rehabilitation
Verified
Journal Article
Open access
PDF file
SRStephanie K Rigot
Stephanie K Rigot
MBMichael L. Boninger
Michael L. Boninger
DDDan Ding
Dan Ding
JCJennifer L. Collinger
Jennifer L. Collinger
BDBrad E. Dicianno
Brad E. Dicianno
LWLynn A. Worobey
Lynn A. Worobey
Background: To evaluate the relationship between measures of neuromuscular impairment and limb accelerations (LA) collected during sleep among individuals with chronic spinal cord injury (SCI) to provide evidence of construct and concurrent validity for LA as a clinically meaningful measure. Methods: The strength (lower extremity motor score), sensation (summed lower limb light touch scores), and spasticity (categorized lower limb Modified Ashworth Scale) were measured from 40 adults with chronic (≥ 1 year) SCI. Demographics, pain, sleep quality, and other covariate or confounding factors were measured using self-report questionnaires. Each participant then wore ActiGraph GT9X Link accelerometers on their ankles and wrist continuously for 1–5 days to measure LA from movements during sleep. Regression models with built-in feature selection were used to determine the most relevant LA features and the association to each measure of impairment. Results: LA features were related to measures of impairment with models explaining 69% and 73% of the variance (R²) in strength and sensation, respectively, and correctly classifying 81.6% (F1-score = 0.814) of the participants into spasticity categories. The most commonly selected LA features included measures of power and frequency (frequency domain), movement direction (correlation between axes), consistency between movements (relation to recent movements), and wavelet energy (signal characteristics). Rolling speed (change in angle of inclination) and movement smoothness (median crossings) were uniquely associated with strength. When LA features were included, an increase of 72% and 222% of the variance was explained for strength and sensation scores, respectively, and there was a 34% increase in spasticity classification accuracy compared to models containing only covariate features such as demographics, sleep quality, and pain. Conclusion: LA features have shown evidence of having construct and concurrent validity, thus demonstrating that LA are a clinically-relevant measure related to lower limb strength, sensation, and spasticity after SCI. LA may be useful as a more detailed measure of impairment for applications such as clinical prediction models for ambulation.

Verified
Journal Article
Open access
PDF file
HAHussein Alawieh
Hussein Alawieh
KSKurtis J Swartz
Kurtis J Swartz
SRStephanie K Rigot
Stephanie K Rigot
JCJonathan D. Charlesworth
Jonathan D. Charlesworth
Background: Restless legs syndrome (RLS) is a prevalent neurological sleep disorder that often impairs sleep maintenance. This single-arm, open-label study evaluated the efficacy, safety, and tolerability of extended-duration tonic motor activation (XD-TOMAC) in adults with RLS who experience frequent awakenings with symptoms. Methods: The study comprised three stages: Stage 1 (2 weeks of no intervention), Stage 2 (8 weeks XD-TOMAC), and Stage 3 (2 weeks of no intervention). XD-TOMAC consisted of bilateral high-frequency peroneal nerve stimulation programmed to 180 min duration and administered nightly at bedtime. Nineteen adults with moderate–severe RLS were enrolled, each reporting at least three nights per week of RLS symptoms causing increased awakenings or interfering with returning to sleep after waking. Results: The intent-to-treat analysis population included all patients who began Stage 2 (n = 15). After 8 weeks of XD-TOMAC, the mean change in International RLS Study Group Rating Scale (IRLS) score was −10.6 points (p < 0.001), and the mean change in Medical Outcomes Study Sleep Problems Index II (MOS-II) was −29.5 points (p < 0.001). The mean change in the number of nocturnal awakenings was −1.1 per night (p = 0.009), and the mean change in sleep efficiency was +8.5% (p = 0.001). The mean change in time awake with RLS symptoms after sleep onset was −28.1 min (p = 0.009). Each of these improvements was sustained at the end of Stage 3 (p < 0.01). There were no serious or severe device-related adverse events. Conclusions: Compared with prior 30 min TOMAC studies, XD-TOMAC demonstrated greater efficacy and similar tolerability, supporting its potential as a nonpharmacological therapy for RLS patients whose symptoms frequently disrupt sleep.